This is a critical detail compounded medications are not FDA-approved as finished products, so the quality of the compounding pharmacy matters enormously
For some individuals, GLP-1 medications may function similarly to long-term treatment for chronic conditions like high blood pressure or diabetes
Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users
The glucagon part raises how many calories the body burns and helps the liver use fat for fuel a step that Semaglutide and Tirzepatide do not have
If your total protocol is 48 weeks, the four weeks you spend at the starting dose represent less than 10% of the total journey
One of the treatments we consider in our personalized healthcare plans is the use of Glucagon-like peptide-1 (GLP-1) injections
